Switching from natalizumab to alemtuzumab in patients with relapsing multiple sclerosis

J Neurol Neurosurg Psychiatry. 2019 Dec;90(12):1376-1378. doi: 10.1136/jnnp-2019-320687. Epub 2019 May 11.

Authors

Nevin John¹, Antonia Carroll², Wallace J Brownlee^{2

3}, Jeremy Chataway^{4

2}

Affiliations

¹ Neuroinflammation, University College London Institute of Neurology, London, UK nevin.john@ucl.ac.uk.
² University College London Hospitals NHS Foundation Trust, National Hospital for Neurology and Neurosurgery, London, UK.
³ Department of Neuroinflammation, Queen Square Multiple Sclerosis Centre, London, UK.
⁴ Neuroinflammation, University College London Institute of Neurology, London, UK.

PMID: 31079064
DOI: 10.1136/jnnp-2019-320687

No abstract available

Keywords: multiple sclerosis.

Publication types

Letter

MeSH terms

Adult
Alemtuzumab / adverse effects
Alemtuzumab / therapeutic use*
Female
Fingolimod Hydrochloride / therapeutic use
Follow-Up Studies
Humans
Integrin alpha4 / antagonists & inhibitors
Leukocyte Count
Male
Multiple Sclerosis, Relapsing-Remitting / drug therapy*
Natalizumab / adverse effects
Natalizumab / therapeutic use*
Neuromuscular Agents / therapeutic use*
Recurrence
Retrospective Studies

Substances

Natalizumab
Neuromuscular Agents
Integrin alpha4
Alemtuzumab
Fingolimod Hydrochloride